Cardiovascular
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake
The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.
CinCor Plans Baxdrostat Phase III Despite Phase II Miss In Uncontrolled Hypertension
With subgroup analysis that it claims shows efficacy in non-Hispanics and success in a previous Phase II in treatment-resistant hypertension, CinCor plans to outline Phase III plans to FDA in early 2023.
CMO Eliav Barr On Merck & Co.'s Post-Keytruda Game Plan
Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.
Acticor Makes Case For First-In-Class Heart Drug Glencozimab
As it initiates the mid-stage clinical program for glencozimab, Acticor says that the potential of the drug in ischemic stroke alone could make it a blockbuster.
Mineralys Looks To Path Ahead For MLS-101 In Hypertension
The company plans to meet with the FDA before the end of the year to discuss the way forward, including a pivotal study it hopes to launch in 2023 in uncontrolled and resistant hypertension.
AstraZeneca To Remain In Vaccines For The Long Haul
The highs and lows experienced with its COVID-19 vaccine Vaxzevria have not deterred the UK giant from keeping a presence in the field and CEO Pascal Soriot told Scrip that the path could mirror the decade-long journey AstraZeneca had in oncology before it achieved sustained success.
Idorsia/J&J’s Aprocitentan Hits Phase III Mark, Could Become First ET-1 Antagonist For Hypertension
The first-in-class ET-1 receptor antagonist has met the primary endpoint in a pivotal resistant hypertension trial, sparking filing plans that could see the drug establish a stronghold in the multi-billion dollar market.
Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class
The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December.
Bayer Goes All In With Asundexian And Pulls Two Other Factor XIa Projects
Despite promising mid-stage data for the Ionis-partnered fesomersen and osocimab, licensed from Aronora, the German major has plumped for asundexian as the priority compound for its Factor XIa efforts.
Milestone Hits Mark With RAPID Path To Potential Blockbuster Sales
The company plans to file for approval of etripamil in paroxysmal supraventricular tachycardia (PSVT) in mid-2023, with the drug having the possibility to reach sales of $1bn or more.
Amarin Fights Flames Of Investor Unrest
Derided by largest shareholder Sarissa as ‘dawdling’ and ‘lackadaisical,’ the board at Amarin has come out fighting, saying that a strategy of growing its heart drug in Europe will pay dividends.
Merck’s Sotatercept Hits Phase III Marks In Mid-Stage PAH Patients
The pharma’s pulmonary arterial hypertension candidate, touted as a future blockbuster seller, showed benefit on six-minute walk distance and several secondary endpoints in Phase III STELLAR.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.